Success Metrics

Clinical Success Rate
96.0%

Based on 48 completed trials

Completion Rate
96%(48/50)
Active Trials
3(5%)
Results Posted
33%(16 trials)
Terminated
2(3%)

Phase Distribution

Ph not_applicable
12
19%
Ph phase_1
11
17%
Ph phase_2
10
16%
Ph phase_3
16
25%
Ph phase_4
9
14%

Phase Distribution

11

Early Stage

10

Mid Stage

25

Late Stage

Phase Distribution58 total trials
Phase 1Safety & dosage
11(19.0%)
Phase 2Efficacy & side effects
10(17.2%)
Phase 3Large-scale testing
16(27.6%)
Phase 4Post-market surveillance
9(15.5%)
N/ANon-phased studies
12(20.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.1%

48 of 51 finished

Non-Completion Rate

5.9%

3 ended early

Currently Active

3

trials recruiting

Total Trials

63

all time

Status Distribution
Active(3)
Completed(48)
Terminated(3)
Other(9)

Detailed Status

Completed48
unknown9
Recruiting3
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
63
Active
3
Success Rate
96.0%
Most Advanced
Phase 4

Trials by Phase

Phase 111 (19.0%)
Phase 210 (17.2%)
Phase 316 (27.6%)
Phase 49 (15.5%)
N/A12 (20.7%)

Trials by Status

withdrawn12%
completed4876%
terminated23%
recruiting35%
unknown914%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT03178149Phase 1

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Recruiting
NCT05589688Phase 1

Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir

Recruiting
NCT03368664Phase 3

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Terminated
NCT06134492Phase 3

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

Recruiting
NCT02073097Phase 1

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed
NCT00495716Phase 4

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

Terminated
NCT00061945Phase 1

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

Completed
NCT02977533Phase 1

A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Completed
NCT05324904Not Applicable

Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts

Unknown
NCT05313828

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Unknown
NCT03831165Phase 4

Melatonin Effects on Genital Herpes in Brazilian Women

Completed
NCT00362297Phase 4

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

Completed
NCT00000712Phase 2

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

Completed
NCT00001010Phase 1

A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

Completed
NCT00000985Phase 3

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

Completed
NCT00000693Not Applicable

Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS

Completed
NCT04132115

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Unknown
NCT02151240Phase 4

Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster

Completed
NCT03389191Not Applicable

A Clinical Trial of Acyclovir for Viral Uveitis

Unknown
NCT02583594Phase 1

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
63